Phaze Clinical Research & Pharma Consulting S.A. is a full-service Contract Research Organization (CRO) established as a Société Anonyme in April 2010 in Athens, Greece. From its first offices on Xenopoulou Street in Neo Psychiko, Phaze has grown into an ISO 9001:2015-certified organization trusted by pharmaceutical, biotechnology, and medical device companies, as well as fellow CROs, universities, and research institutions, to deliver clinical trials in Greece and beyond.
Vision, Mission, and Values
Phaze describes its vision as being a committed and fully reliable partner for pharmaceutical, biotechnology, and CRO companies and medical researchers, in Greece and internationally, always offering the maximum of its capabilities in quality, flexibility, initiative, and effectiveness. Its mission centres on the proper use of knowledge, experience, and trusted relationships to accurately and reliably deliver clinical study results across all phases (I–IV), so that Phaze can become a meaningful partner in the development and promotion of new medicines and technologies.
Underpinning this is a clear set of values: people come first — colleagues, collaborators, clients, physicians, and, above all, patients; relationships are built on mutual trust; leadership is grounded in transparency, honesty, and moral integrity; open communication runs through every level of the organization; and quality, team spirit, and continuous improvement guide how clinical development programmes are managed day to day.
A History Built on Quality and Continuous Growth
Phaze’s history reflects a steady, deliberate build-up of capability and credibility. The company began operating in June 2010 with Clinical Operations, Data Management, and Biostatistics services, and its first Standard Operating Procedures became effective just a few months later. Within its first year, Phaze had already expanded into Market Research, Medical Translations and Writing, and Clinical Quality Assurance, and in 2012 it became a founding member of the Hellenic Association of CROs (HACRO).
Quality has been a constant thread throughout this growth: an external SOP review as early as 2011, a Code of Conduct in 2013, successful participation in the Pharmaceutical Supply Chain Initiative sustainability audit, and formal registration in the National Registry of CROs of the Greek National Organization for Medicines (EOF) in 2017. In March 2019, Phaze completed ISO 9001:2015 certification, following a company-wide restructuring of its policies, procedures, and Quality Management System — an achievement it has successfully reassessed every year since. Phaze has also established a dedicated Data Protection Officer to ensure compliance with the GDPR, and maintains Civil Liability insurance to protect the interests of its sponsors and study participants alike. More recently, in 2021, Phaze partnered with the Athens Medical Society to launch the Academy of Clinical Trials, a training programme run twice yearly for scientific and research professionals.
Experience That Sponsors Can Rely On
One of Phaze’s defining strengths is the depth of experience its people bring to every project. As of 2025, Phaze’s employees average 11.2 years of experience in clinical research, its management team averages 20.4 years in clinical trial conduct, and its CRA team averages 7.6 years in the field — figures that translate into fewer surprises and steadier delivery for sponsors. All staff are trained in ICH/GCP and the company’s own SOPs, with continuous training built into how the organization operates.
That experience has been put to work across a broad client base: Phaze has collaborated with major international and Greek pharmaceutical companies, leading Greek universities and medical societies on investigator-initiated studies, and other CROs and biotech companies — 48 organizations in total. Its service offering spans project management, regulatory submissions and clinical contract management, clinical monitoring, data management and biostatistics, pharmacovigilance, medical writing, medical and scientific translation, and clinical quality assurance — as well as clinical research training. The team’s strengths, as Phaze itself puts it, come down to knowledge, experience, flexibility, customer focus, financial transparency, open communication, and price-competitive services.
Beyond day-to-day trial operations, Phaze’s team has developed particular depth in European regulatory frameworks — including the Clinical Trials Regulation (EU) No 536/2014, the Medical Device Regulation (EU) 2017/745, and the Clinical Trials Information System (CTIS) — with therapeutic-area experience spanning oncology, neurology, haematology, and medical device trials. This combination of scientific depth and regulatory precision is what has allowed Phaze to remain a dependable partner for sponsors and consortia navigating an increasingly complex clinical research landscape.
Phaze’s Role in ThrombUS+
Within the ThrombUS+ consortium, Phaze serves as the project’s Contract Research Organization and leads Work Package 7, which covers the clinical validation of the ThrombUS+ wearable device. Phaze’s role is to provide the regulatory, operational, and project management expertise needed to bring the project’s clinical programme to life across every jurisdiction involved.
Concretely, this means Phaze is responsible for the start-up, coordination, and ongoing supervision of the clinical studies that make up the ThrombUS+ clinical validation plan, across sites in Greece, Italy, France, and Lithuania. This work involves steering studies through national ethics committees and competent authorities, ensuring Good Clinical Practice compliance at every site, and managing the regulatory particularities that come with testing a novel, non-CE marked prototype device.
Beyond the regulatory dimension, Phaze’s team supports the day-to-day realities of running a multi-country clinical programme: liaising with investigators and site staff, coordinating recruitment across studies, preparing clinical and regulatory documentation, and contributing to the project’s periodic reporting to the European Commission, including recruitment updates and clinical deliverables.
Committed to the ThrombUS+ Mission
Deep vein thrombosis is a condition where early detection can make a life-changing difference, and Phaze is proud to contribute its clinical and regulatory expertise to a project working to make that early detection possible through wearable technology. By helping steer the ThrombUS+ clinical studies safely and compliantly through some of Europe’s most demanding regulatory pathways, Phaze aims to help ensure that the innovation being developed within this consortium can, one day, reach the patients who need it.
Phaze looks forward to continuing this collaboration with its fellow ThrombUS+ partners as the project moves toward its next milestones.
